A phase II/III trial of PSA-IL2-GM-CSF-vaccine for the treatment of PSA recurrent prostate cancer in hormone-naive and hormone-independent patients

Trial Profile

A phase II/III trial of PSA-IL2-GM-CSF-vaccine for the treatment of PSA recurrent prostate cancer in hormone-naive and hormone-independent patients

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors OncBioMune Mexico
  • Most Recent Events

    • 27 Jun 2017 According to an OncBioMune Pharmaceuticals media release, Mexico health authority, Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS) has officially authorized commencement of this trial. The company is now working with the host hospital, principal investigators and others involved in the trial to begin enrollment immediately
    • 27 Jun 2017 Status changed from planning to not yet recruiting, as reported in an OncBioMune Pharmaceuticals media release.
    • 21 Jun 2017 According to an OncBioMune Pharmaceuticals media release, the company expect to announce the official commencement of this trial any day now.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top